Reuters GlaxoSmithKline and Henderson Global Investors

Henderson Global Investors: Reuters GlaxoSmithKline GSK .L may have closed one chapter in a saga of corruption allegations by accepting a $489 million 299.36 million pounds fine in China, but the drugmaker has its work cut out to win back sceptical investors, according to Euro News. I think GSK is a buy when the CEO of that business goes, said John Bennett, a director of European equities at Henderson Global Investors, which has a holding in the drugmaker and By Ben Hirschler and Simon Jessop That means continued pressure on Chief Executive Andrew Witty, seen not so long ago as one of the sectors star managers, who is under fire for allowing the erosion of GSKs all-important U.S. business just as much as for the woes in China. (news.financializer.com). As reported in the news.